Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Sponsor
Pfizer
Study ID
NCT05701007
Status
Completed

Conditions

  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • abiraterone — DRUG
    mCRPC
  • enzalutamide — DRUG
    mCRPC
  • docetaxel — DRUG
    mCRPC
  • apalutamide — DRUG
    mCRPC
  • cabazitaxel — DRUG
    mCRPC
  • Radium-223 — DRUG
    mCRPC
  • Lutetium-177 — DRUG
    mCRPC
  • degarelix — DRUG
    mCSPC
  • goserelin — DRUG
    mCSPC
  • leuprorelin — DRUG
    mCSPC
  • triptorelin — DRUG
    mCSPC

Study Details

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?

Key Dates

Start date
Feb 13, 2023
Status verified
Jan 2026
Primary completion
Apr 10, 2024
Completion
Apr 10, 2024

Study Design

Enrollment
1,083 participants (actual)

Arms

  • Arm: Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)
  • Arm: Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)

Primary Outcome Measure

Body Mass Index (BMI) [ Time Frame: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months ]

Related Studies